Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights.

Abstract

BACKGROUND:

Transfer delays for primary percutaneous coronary intervention may increase mortality in patients with ST-segment-elevation myocardial infarction. We examined the association between door 1-to-door 2 (D1D2) time, a measure capturing the entire transfer process, and outcomes in patients undergoing interhospital transfer for primary percutaneous coronary intervention.

METHODS AND RESULTS:

We evaluated the relationship between D1D2 time and the 90-day incidence of death, shock, and heart failure in the subset of 2075 (36.1%) of 5745 patients who underwent interhospital transfer for primary percutaneous coronary intervention in the Assessment of Pexelizumab in Acute Myocardial Infarction trial. There was no significant difference in the 90-day incidence of death, shock, and heart failure between the transferred and the nontransferred groups (10.3% versus 10.2%; P = 0.89). The median difference in symptom-to-balloon time between the 2 groups was 45 minutes (229 versus 184; P<0.001). The primary outcome per 30-minute delay was higher for patients with a D1D2 time ≤150 minutes (hazard ratio, 1.19: 95% confidence interval, 1.06 to 1.33; P = 0.004) but not for D1D2 times >150 minutes (hazard ratio, 0.99: 95% confidence interval, 0.96 to 1.02; P = 0.496). The association between longer D1D2 time and worsening outcome was no longer statistically significant after multivariable adjustment.

CONCLUSIONS:

Longer transfer times were associated with higher rate of death, shock, and heart failure among patients undergoing interhospital transfer from primary percutaneous coronary intervention, although this difference did not persist after adjusting for baseline characteristics.

• Authors: Sean van Diepen, Petr Widimsky, Renato D Lopes, Kyle R White, W Douglas Weaver, Frans Van de Werf, Diego Ardissino, Arnoud W J van't Hof, Paul W Armstrong, Christopher B Granger
• Journal: Circulation. Cardiovascular quality and outcomes (Circ Cardiovasc Qual Outcomes) Vol. 5 Issue 4 Pg. 437-44 (Jul 01 2012) ISSN: 1941-7705 [Electronic] United States
• PMID: 22589297 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal, Humanized
• Single-Chain Antibodies
• pexelizumab

Topics

• Aged
• Angioplasty, Balloon, Coronary (adverse effects, mortality)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Chi-Square Distribution
• Delivery of Health Care, Integrated
• Double-Blind Method
• Female
• Health Services Accessibility
• Health Services Research
• Heart Failure (etiology, mortality)
• Humans
• Male
• Middle Aged
• Multivariate Analysis
• Myocardial Infarction (diagnosis, mortality, therapy)
• Outcome and Process Assessment, Health Care
• Patient Transfer
• Proportional Hazards Models
• Prospective Studies
• Risk Assessment
• Risk Factors
• Shock (etiology, mortality)
• Single-Chain Antibodies (therapeutic use)
• Survival Analysis
• Time Factors
• Time-to-Treatment
• Treatment Outcome